Company profile
Global biopharma, vaccines, specialty medicines · Brentford, London, United Kingdom · gsk.com
GSK is a global biopharma company focused on specialty medicines, vaccines, selected general medicines. Public filings and earnings point to a strategy centered on execution, pipeline acceleration, selective business development, with technology and AI increasingly embedded in R&D and operations.
Management says the company has a clear strategy to build a high quality portfolio in these two areas.
Chair and CEO statements in the 2025 annual report describe specialty medicines and vaccines as the core strategic focus.
Leadership is emphasizing delivery, pace, accountability, focus.
The CEO said the priority is delivery and overall operational execution, with a push to simplify how the company works.
The company is using R&D progress and targeted deals to support future growth.
The 2025 annual report cites 17 phase III or registration assets, 5 major approvals, 14 new collaborations and acquisitions.
GSK is expanding the use of AI and advanced digital technology across science and manufacturing.
A 2026 U.S. investment announcement included new AI and advanced digital technology capabilities across existing manufacturing sites and a next generation biologics factory powered by AI.
GSK to invest 30 billion in R&D and manufacturing in the United States over next 5 years
GSK presents technology as a core operating capability, with cloud posture not publicly detailed in the opened sources.
Strong AI and data orientation in R&D, manufacturing, supplier processes, but limited public disclosure of cloud architecture or named cloud providers in the opened sources.
This is a neutral public preview. Sign in to generate your own personalized brief, with stakeholder angles, talk tracks and where your solution fits, tailored to how you sell.
Generate a full briefYour first brief is free, no card required.
Evidence confidence 86/100. Generated 2026-07-03 from public sources.